Banner

Oncardia Oncology Imaging

Double exposure of abstract virtual chemistry hologram on Los Angeles city skyscrapers background, research and development concept

Text

<h2 style="white-space:pre-line"><span style="color:#3598db">Cancer Imaging</span></h2>
<p>Tc-Oncardia is a target specific sugar analogue radiopharmaceutical specifically developed for use with SPECT and SPECT/CT cameras to image cancer. SPECT cameras are found in over 90% of the world’s hospitals. Prior to Tc-Oncardia, the only way to perform a molecular image in cancer was with 18F-FDG used with PET cameras which remain comparatively expensive and found in less than 2% of the world’s hospitals. Cell Theranostics is sponsoring a Phase 3 lung cancer imaging trial for Oncardia under an FDA approved Special Protocol Assessment (SPA). Oncardia offers many advantages over FDG-PET imaging including access, cost, and the ability to monitor therapy during the course of the patient’s therapy.</p>
<p><strong>Past and Current Clinical Trial Sites:</strong></p>
<ul style="list-style-type:square">
<li>University of British Columbia</li>
<li>The University of Texas M.D. Anderson Cancer Center</li>
<li>University of Chicago Medical Center</li>
<li>Johns Hopkins Hospital</li>
<li>Mayo Clinic</li>
<li>Decatur Memorial Hospital</li>
<li>Montefiore Medical Center</li>
<li>Baptist Health</li>
<li>St. Louis University Medical Center</li>
<li>John Cochran VA Medical Center</li>
</ul>